VIRAMUNE ORAL SUSPENSION(nevirapine)
Nevirapine (as hemihydrate) 50mg/5mL.
Company:
Boehringer Ingelheim Pharmaceuticals

Select therapeutic use: Viral infections
Indications for VIRAMUNE ORAL SUSPENSION:
HIV-1 infection.

Adult:
≥16yrs: Initially 200mg once daily for 14 days. If no rash occurs, increase to 200mg twice daily. If mild-to-moderate rash occurs during the 14-day lead in period, do not give twice-daily regimen until rash has resolved; lead-in dosing regimen should not be continued beyond 28 days, consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Max 400mg/day. Retitrate if stopped for >7days. Hemodialysis: give additional nevirapine 200mg dose after dialysis.

Children:
<15 days: not recommended. For oral susp: use dosing syringe or cup: ≥15 days: Initially 150mg/m2 once daily for 14 days; if no rash occurs increase to 150mg/m2 twice daily. If mild-to-moderate rash occurs during the 14-day lead in period, do not give twice-daily regimen until rash has resolved; lead-in dosing regimen should not be continued beyond 28 days, consider alternative regimen. If severe rash or hepatic event occurs, discontinue permanently. Max 400mg/day. Retitrate if stopped for >7 days.

Contraindications:
Moderate-to-severe (Child-Pugh B or C) hepatic impairment. Use as part of occupational or non-occupational post-exposure prophylaxis regimens.

Warnings/Precautions:
Women with CD4 counts >250cells/mm3 or men with CD4 counts >400cells/mm3 (increased risk of rash-associated hepatic events): usually not recommended (see full labeling). Monitor liver function (at baseline, during 1st 18 weeks, and throughout therapy). Suspend and discontinue permanently if signs/symptoms of hepatitis, elevated transaminases, severe rash, or rash with constitutional symptoms (eg, fever, blistering, oral lesions, conjunctivitis, swelling, muscle/joint aches or general malaise) occurs; do not restart after recovery. Co-infected with hepatitis B or C. Hepatitis fibrosis or cirrhosis; monitor. Renal dysfunction. Elderly. Pregnancy (Cat.B). Nursing mothers: not recommended.

Interactions:
Possible increased adverse reactions with concomitant efavirenz: not recommended. Concomitant other NNRTIs: not recommended. Potentiated by fluconazole (monitor). Antagonizes atazanavir, fosamprenavir without ritonavir, ketoconazole, itraconazole, boceprevir, telaprevir, oral contraceptives (use nonhormonal contraception): not recommended, clarithromycin (consider alternative). Antagonized by St. John's wort, rifampin: not recommended. May antagonize methadone (monitor for withdrawal symptoms; increase methadone dose if needed), or drugs metabolized by CYP3A4 or CYP2B6. Do not give lopinavir/ritonavir tabs or oral soln once daily with nevirapine (see full labeling). Monitor warfarin, carbamazepine, clonazepam, ethosuximide, rifabutin, other CYP450 substrates.

See Also:
VIRAMUNE

VIRAMUNE XR

Pharmacological Class:
Non-nucleoside reverse transcriptase inhibitor.

Adverse Reactions:
Potentially severe, life-threatening hepatotoxicity (eg, hepatic necrosis, cholestatic hepatitis) or skin reactions (eg, Stevens-Johnson syndrome, toxic epidermal necrolysis); nausea, headache, abnormal liver function tests, fatigue, fever, vomiting, myalgia, abdominal pain, fat redistribution, immune reconstitution syndrome. Children: also granulocytopenia.

Note:
Register pregnant patients exposed to nevirapine by calling (800) 258-4263.

How Supplied:
Tabs—60; Susp—240mL; XR 100mg—90; 400mg—30